JPH114666A - Foaming agent composition for supplying magnesium - Google Patents

Foaming agent composition for supplying magnesium

Info

Publication number
JPH114666A
JPH114666A JP9159454A JP15945497A JPH114666A JP H114666 A JPH114666 A JP H114666A JP 9159454 A JP9159454 A JP 9159454A JP 15945497 A JP15945497 A JP 15945497A JP H114666 A JPH114666 A JP H114666A
Authority
JP
Japan
Prior art keywords
magnesium
foaming agent
composition
present
weight
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP9159454A
Other languages
Japanese (ja)
Inventor
Akihisa Takaichi
晶久 高市
Toshihiko Okamoto
俊彦 岡本
Toshiaki Matsumoto
敏明 松本
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Otsuka Pharmaceutical Co Ltd
Original Assignee
Otsuka Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Otsuka Pharmaceutical Co Ltd filed Critical Otsuka Pharmaceutical Co Ltd
Priority to JP9159454A priority Critical patent/JPH114666A/en
Publication of JPH114666A publication Critical patent/JPH114666A/en
Pending legal-status Critical Current

Links

Landscapes

  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Non-Alcoholic Beverages (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

PROBLEM TO BE SOLVED: To obtain a magnesium-supplying foaming agent composition light in weight, extremely good in taste, easy in intake and administration and excellent in stability, uniformity and practicality by including magnesium sulfate, a foaming agent component and a neutralizing agent component in a specific ratio. SOLUTION: This magnesium-supplying foaming agent composition comprises (A) 0.6-6 wt.% (as magnesium) of magnesium sulfate, (B) 10-35 wt.% of a foaming agent such as potassium bicarbonate, and (C) 15-60 wt.% of a neutralizing agent component comprising 20-30 wt.% of citric acid and L-tartaric acid and 5-25 wt.% of L-ascorbic acid. The composition preferably further contains 0.2-13 wt.% of potassium carbonate and 0.2-13 wt.% of potassium carbonate, and the composition is preferably prepared in the form of tablets, granules, powders or capsules.

Description

【発明の詳細な説明】DETAILED DESCRIPTION OF THE INVENTION

【0001】[0001]

【発明の属する技術分野】本発明はマグネシウム補給発
泡剤組成物、より詳しくはマグネシウム分の生体への補
給を行ない得、改善された製剤特性を有するマグネシウ
ム補給発泡剤組成物に関する。
BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention relates to a magnesium supplemented foaming composition, and more particularly to a magnesium supplemented foaming composition capable of supplying magnesium to a living body and having improved pharmaceutical properties.

【0002】[0002]

【従来の技術】マグネシウム(Mg)は、生体において
その50%以上は骨に、残りは柔組織、特に細胞内液に
それぞれ分布し、生命維持に必要不可欠な生理作用を担
っている。このMgが不足すると、生体は種々の病理状
態に陥ることが知られている。例えばMgが欠乏状態に
なると、抑うつ症に罹患し、不安感、感情の鈍化、更に
は興奮、精神錯乱等の精神障害が惹起される。また該M
gの摂取不足が続くと疲労感が著しくなり、心身が不調
となることが知られており、更に発言や文字を書くこと
が不自由になったりする事例も報告されている。
2. Description of the Related Art Magnesium (Mg) is distributed in bone in an amount of 50% or more in a living body, and is distributed in a parenchyma tissue, particularly in an intracellular fluid, and plays a physiological function indispensable for maintaining life. It is known that when this Mg is insufficient, the living body falls into various pathological states. For example, when Mg is deficient, the patient suffers from depression, causing anxiety, slowing of emotions, and further mental disorders such as excitement and mental confusion. The M
It is known that if the intake of g continues to be inadequate, the feeling of fatigue becomes remarkable, and the body and mind become unwell. In addition, there have been reports of cases in which it is difficult to speak or write.

【0003】上記Mgは、またカルシウム(Ca)と拮
抗的な機能を分担しており、従ってMg不足になるとC
aの代謝も乱れ、該Caが血管や内臓組織に沈着し、動
脈硬化、腎臓結石等を引き起こすおそれがあるに加え、
該Mg不足はナトリウム(Na)やカリウム(K)を含
む多量ミネラル全般の正しい代謝をも妨げ、循環器系疾
患の発病の引き金となり、突然死の一因となるとも報告
されている。
[0003] Mg also has an antagonistic function with calcium (Ca).
In addition, the metabolism of a may be disturbed, and the Ca may be deposited on blood vessels and visceral tissues, causing arteriosclerosis, kidney stones, and the like.
It has also been reported that the Mg deficiency also interferes with the correct metabolism of large amounts of minerals including sodium (Na) and potassium (K), triggers the onset of cardiovascular diseases, and contributes to sudden death.

【0004】上記Mgは、玄米や大豆、小豆等の豆類に
多く含まれているが、今世紀、特に戦後、精製加工食
品、インスタント食品等の普及が加速されるに従い、該
Mgの摂取不足が深刻な問題となってきている。特に成
人におけるMgの目標摂取量は一日300mgと設定さ
れているが、現在の成人一人の一日摂取量はおよそ20
0mg程度といわれ、明らかに摂取不足が認められる。
この摂取不足と共に、Mgは現代社会における各種の精
神ストレスや飲酒等によって損失することが知られてい
る。
[0004] The above Mg is contained abundantly in beans such as brown rice, soybeans, red beans and the like, but as the spread of refined processed foods, instant foods, etc. is accelerated, especially in the postwar period, the shortage of intake of the Mg is serious. Has become a major problem. In particular, the target intake of Mg for adults is set at 300 mg per day, but the current daily intake per adult is about 20 mg.
It is said to be about 0 mg, and there is clearly a lack of intake.
It is known that with this insufficient intake, Mg is lost due to various mental stresses and drinking in modern society.

【0005】また、上記の通りMgとCaとの拮抗的機
能分担より、之等には適正な摂取バランスがあり、それ
は一般にMg/Ca=1/2であるといわれている。し
かるに、近年、日本人のCa摂取不足が深刻となり、そ
の摂取量増加に大きな注意が払われるに至り、該Caの
補給を目的とする各種医薬品や健康食品等が種々研究、
開発され、カレーやふりかけその他の加工食品にまでC
a添加が普及してきたが、このようなCa補給剤はその
Mg含量については全く考慮がなされておらず、従って
これを摂取すれば、むしろ上記Mg/Ca摂取比率が1
/4〜1/5となり、その摂取バランスの著しい低下を
招く。このアンバランスは、循環器疾患、特に虚血性心
疾患を惹起させる要因となる。このように、Ca摂取量
の増加はそれ自体重要ではあるが、同時にMg摂取量と
のバランスを考慮したものでなければならない。
[0005] Further, as described above, due to the antagonistic function sharing between Mg and Ca, they have an appropriate intake balance, and it is generally said that Mg / Ca = 1/2. However, in recent years, the lack of Ca intake by the Japanese people has become serious, and great attention has been paid to the increase in the intake of Ca.
Developed to curry, sprinkle and other processed foods C
Although the addition of a has become widespread, such Ca supplements are not considered at all with regard to their Mg content.
/ 4 to 1/5, resulting in a marked decrease in the intake balance. This imbalance causes a cardiovascular disease, particularly an ischemic heart disease. Thus, the increase in Ca intake is important in itself, but at the same time, it must be balanced with the Mg intake.

【0006】以上のように、現代人は、摂取量不足、ス
トレス等による損失、Ca補給によるMg/Ca摂取バ
ランスの不均衡化等により、深刻なMg不足に陥ってお
り、前記各種疾患に罹患する危機にさらされている。
As described above, modern people suffer from severe Mg deficiency due to lack of intake, loss due to stress, etc., and imbalance in Mg / Ca intake balance due to Ca supplementation, and suffer from the various diseases described above. You are in danger.

【0007】一方、従来より、Mgを含む食品添加物と
しては、酸化マグネシウム、塩化マグネシウム、炭酸マ
グネシウム、硫酸マグネシウム及びリン酸マグネシウム
が知られているが、この内、酸化マグネシウムは、食品
衛生法上、食品の加工上必要不可欠であって且つ吸着目
的の場合以外は用いてはならず、炭酸マグネシウムも膨
脹剤として食品加工上必要不可欠の場合を除いては利用
してはならず、しかもこれはその食品中への残存量が
0.5重量%以下でなければならないという規制があ
る。また塩化マグネシウム及び硫酸マグネシウムは、苦
汁の主成分として知られるものであり、いずれも強い苦
みを呈する不利があり、Mg補給剤としての使用は到底
できない現状にある。
On the other hand, as a food additive containing Mg, magnesium oxide, magnesium chloride, magnesium carbonate, magnesium sulfate, and magnesium phosphate have been conventionally known. Of these, magnesium oxide is defined by the Food Sanitation Law. , Must not be used except for the purpose of food processing and for the purpose of adsorption, and magnesium carbonate must not be used as a swelling agent except in the case of food processing. There is a regulation that the residual amount in the food must be 0.5% by weight or less. Magnesium chloride and magnesium sulfate are known as main components of bitterness, and both have the disadvantage of exhibiting strong bitterness, and at present there is no use as a Mg supplement.

【0008】[0008]

【発明が解決しようとする課題】従って本発明の目的
は、現代人の陥っているMgの不足、Ca摂取とのアン
バランス是正等に対して有効な、新しいMg補給組成
物、殊に実用性が高く、製剤形態での均一性、安定性に
優れ、摂取や服用が容易(飲みやすく、味等に優れてい
る)で、しかも充分なMgを安定して補給できる発泡製
剤形態の組成物を提供することにある。
SUMMARY OF THE INVENTION Accordingly, an object of the present invention is to provide a new Mg replenishing composition which is effective for the deficiency of Mg and correction of imbalance with Ca intake, etc. The composition is in the form of a foamed product that is highly uniform, has excellent uniformity and stability in the form of the preparation, is easy to ingest and take (easy to drink, has excellent taste, etc.), and can supply a sufficient amount of Mg stably. To provide.

【0009】本発明者らは、上記目的より鋭意研究を重
ねた結果、Mg含有化合物として硫酸マグネシウムを所
定割合で必須成分として利用し、これに所定量の発泡剤
成分、中和剤成分等を添加配合して発泡製剤形態とした
組成物が、上記目的に合致することを見出し、ここに本
発明を完成するに至った。
The inventors of the present invention have conducted intensive studies for the above purpose, and have found that magnesium sulfate is used as a Mg-containing compound at a predetermined ratio as an essential component, and a predetermined amount of a foaming agent component, a neutralizing agent component, and the like are added thereto. It has been found that a composition obtained by adding and blending into a foamed preparation meets the above-mentioned object, and the present invention has been completed.

【0010】[0010]

【課題を解決するための手段】本発明によれば、硫酸マ
グネシウムをMgとして0.6〜6重量%、発泡剤10
〜35重量%及び中和剤15〜60重量%を含有する発
泡製剤であることを特徴とするMg補給発泡剤組成物が
提供される。
According to the present invention, magnesium sulfate is 0.6 to 6% by weight as Mg, and a blowing agent 10 is used.
There is provided an Mg-supplemented blowing agent composition, characterized in that it is an effervescent formulation containing -35% by weight and 15-60% by weight of neutralizing agent.

【0011】本発明製剤組成物は、発泡剤形態としたこ
とに基づいて、水分散性、溶解性、摂取容易性等が改善
されている。殊に本発明Mg補給発泡剤組成物は、錠
剤、顆粒剤、カプセル剤等の形態で保存安定性に優れて
おり、溶解性、分散性も良好で、用時水中に投入するだ
けで中和による炭酸ガスの発生を伴って、製剤中に含有
される硫酸マグネシウムを水中に容易に且つ均一に溶
解、分散させ得、この溶液は服用(経口投与)が非常に
容易でしかも美味しい特徴を有すると共に、該服用によ
って生体に充分なMgを補給、吸収させ得る。従ってそ
の利用によれば、Mg欠乏症等の治癒、改善効果が期待
でき、またMg不足傾向にある現代人に、充分なMgを
摂取、補給させて、上記Mg欠乏症に陥る危険を回避し
て、健康状態を維持させ得る効果を奏する。
The pharmaceutical composition of the present invention has improved water dispersibility, solubility, ease of ingestion, etc. based on the form of a foaming agent. In particular, the Mg-supplemented foaming agent composition of the present invention has excellent storage stability in the form of tablets, granules, capsules, etc., has good solubility and dispersibility, and is neutralized simply by putting it in water at the time of use. Can easily and uniformly dissolve and disperse the magnesium sulfate contained in the formulation in water with the generation of carbon dioxide by this method, and this solution has a very easy to take (oral administration) and delicious characteristics, and By taking the drug, a sufficient amount of Mg can be supplied and absorbed to the living body. Therefore, according to its use, healing and improvement effects of Mg deficiency and the like can be expected, and modern humans who are liable to Mg deficiency can be ingested and replenished with sufficient Mg to avoid the risk of falling into the Mg deficiency. It has the effect of maintaining a healthy state.

【0012】[0012]

【発明の実施の形態】本発明組成物においては、Mgと
して硫酸マグネシウムの利用を必須とする。該硫酸マグ
ネシウムは、水に対する溶解性、殊に発泡剤形態とした
ときの溶解性が良好であり、潮解性や吸湿性も小さく、
それ自体安定である利点がある。また、これは、それ自
体本来苦味を有しているが、本発明組成物によれば、発
泡剤成分、中和剤成分、安定剤等の併用に基づいて、ミ
ネラルバランスが調整され、かくして苦みが柔和され、
味に膨らみ及び丸みを持たせることができる。
DETAILED DESCRIPTION OF THE INVENTION In the composition of the present invention, it is essential to use magnesium sulfate as Mg. The magnesium sulfate has good solubility in water, particularly when it is in the form of a foaming agent, and has low deliquescence and hygroscopicity,
It has the advantage of being stable in itself. In addition, this inherently has bitterness itself, but according to the composition of the present invention, the mineral balance is adjusted based on the combination of the foaming agent component, the neutralizing agent component, the stabilizer and the like, and thus Is softened,
The taste can be swelled and rounded.

【0013】しかるに、従来よりMg源として知られて
いる、例えば塩化マグネシウムは、同様に水に対する溶
解性は良好であるが、潮解性があり、取り扱いが困難で
あるに加えて、非常に苦い味を有しており、服用に適し
たものではない。炭酸マグネシウムや酸化マグネシウム
は、無味・無臭である利点はあるが、法律上食品に対す
る使用制限があり、Mg補給の目的を満たす量での利用
は困難である難点があり、また、単体では水に不溶であ
り、酸(中和剤)との反応によっても水に対する溶解性
を充分なものとはできない不利もある。その他のMg源
としての化合物、例えばクエン酸マグネシウム、酢酸マ
グネシウム、グルコン酸マグネシウム、アスパラギン酸
マグネシウム、硝酸マグネシウム、ケイ酸アルミン酸マ
グネシウム、ケイ酸マグネシウム等は、総じて、水に対
する溶解性が劣悪であり、溶解時間の延長、沈殿物の発
生、溶解液に濁り発生等の欠点があり、しかもMg含有
率が比較的小さい場合が多く、所定サイズの製剤中に必
要量を添加配合し難い難点もあり、更に苦み等が著し
く、味が悪い欠点もある。
[0013] However, magnesium chloride, which is conventionally known as an Mg source, has good solubility in water, but is deliquescent and difficult to handle, and has a very bitter taste. It is not suitable for taking. Magnesium carbonate and magnesium oxide have the advantage of being tasteless and odorless, but there are legal restrictions on the use of food, and it is difficult to use them in amounts that satisfy the purpose of Mg supplementation. It is insoluble, and there is a disadvantage that its solubility in water cannot be made sufficient even by reaction with an acid (neutralizing agent). Compounds as other Mg sources, for example, magnesium citrate, magnesium acetate, magnesium gluconate, magnesium aspartate, magnesium nitrate, magnesium silicate, magnesium silicate, etc., generally have poor solubility in water, There are drawbacks such as prolongation of dissolution time, generation of precipitates, generation of turbidity in the dissolution solution, and the Mg content is often relatively small, and it is difficult to add the required amount to a preparation of a predetermined size. Furthermore, there is a disadvantage that bitterness is remarkable and taste is bad.

【0014】本発明における必須成分としての上記硫酸
マグネシウムは、特に制限されるものではないが、通常
入手される形態、一般には粒度が350μm以下の粉末
形態で、本発明に有利に利用できる。その配合量はMg
として0.6〜6%(重量%、以下同じ)、好ましくは
1〜4%の範囲から選択されるのがよい。
The magnesium sulfate as an essential component in the present invention is not particularly limited, but can be advantageously used in the present invention in a commonly available form, generally in a powder form having a particle size of 350 μm or less. The compounding amount is Mg
It is good to be selected from the range of 0.6 to 6% (% by weight, hereinafter the same), preferably 1 to 4%.

【0015】本発明組成物は、発泡剤形態を有してお
り、該発泡剤は上記特定のMg化合物を所定割合で含有
すると共に、発泡剤成分と中和剤成分とを所定量含有す
ることを必須としている。ここで用いられる発泡剤成分
は、炭酸水素カリウム、炭酸カリウム、炭酸水素ナトリ
ウム、炭酸ナトリウム、炭酸マグネシウム及び炭酸カル
シウムから選択され、之等は1種単独でも使用でき、ま
た2種以上を併用することもできる。
The composition of the present invention has a form of a foaming agent. The foaming agent contains the above-mentioned specific Mg compound at a predetermined ratio, and also contains a predetermined amount of a foaming agent component and a neutralizing agent component. Is required. The foaming agent component used here is selected from potassium bicarbonate, potassium carbonate, sodium bicarbonate, sodium carbonate, magnesium carbonate, and calcium carbonate. These can be used alone or in combination of two or more. Can also.

【0016】中和剤成分としては、上記発泡剤成分化合
物を中和させて炭酸ガスを発生させ得る酸性化合物を使
用する。該酸性化合物には、例えば代表的にはL−酒石
酸、クエン酸、フマル酸、L−アスコルビン酸、グルコ
ン酸、酢酸、乳酸、リンゴ酸等の有機酸が包含される。
As the neutralizing agent component, an acidic compound capable of generating carbon dioxide by neutralizing the foaming agent component compound is used. The acidic compound typically includes, for example, organic acids such as L-tartaric acid, citric acid, fumaric acid, L-ascorbic acid, gluconic acid, acetic acid, lactic acid, and malic acid.

【0017】上記発泡剤成分及び中和剤成分の本発明組
成物中への配合割合は、得られる本発明発泡製剤組成物
を水に溶解させた場合に、溶液が酸性、特にpH約3.
6〜5.1程度、好ましくは約4.0〜4.7程度の酸
性を呈するものとなる割合とするのがよい。より具体的
には上記割合は発泡剤成分10〜35%及び中和剤成分
15〜60%の範囲から選択されるのがよい。
The mixing ratio of the above-mentioned foaming agent component and neutralizing agent component to the composition of the present invention is such that when the obtained foamed pharmaceutical composition of the present invention is dissolved in water, the solution is acidic, and particularly the pH is about 3.
The ratio is preferably such that the acidity is about 6 to 5.1, preferably about 4.0 to 4.7. More specifically, the above ratio is preferably selected from the range of 10 to 35% of the foaming agent component and 15 to 60% of the neutralizing agent component.

【0018】特に発泡剤成分としての炭酸ナトリウムは
0〜23%、好ましくは5〜15%、炭酸水素ナトリウ
ムは0〜35%、好ましくは10〜250%、炭酸カリ
ウムは0.2〜13%、好ましくは2〜10%、炭酸水
素カリウムは0〜19%、好ましくは5〜15%、炭酸
カルシウムは0.2〜13%、好ましくは2〜10%、
炭酸マグネシウムは約0.5%以下の範囲から選ばれる
のがよい。
In particular, sodium carbonate as a foaming agent component is 0 to 23%, preferably 5 to 15%, sodium bicarbonate is 0 to 35%, preferably 10 to 250%, potassium carbonate is 0.2 to 13%, Preferably 2-10%, potassium bicarbonate 0-19%, preferably 5-15%, calcium carbonate 0.2-13%, preferably 2-10%,
Magnesium carbonate is preferably selected from a range of about 0.5% or less.

【0019】本発明者らは、上記発泡剤成分として利用
され得る炭酸カリウムが、炭酸カルシウムと共に、硫酸
マグネシウムの安定剤(苦み防止剤)としても機能する
ことを見出した。従って、本発明Mg補給発泡剤組成物
は、かかる炭酸カリウム及び炭酸カルシウムの添加配合
が重要であり、これによって、本発明所期の効果が達成
される。之等を添加配合した本発明組成物の特に好まし
い組成としては、以下のものを例示することができる。
The present inventors have found that, together with calcium carbonate, potassium carbonate which can be used as the above-mentioned foaming agent component also functions as a magnesium sulfate stabilizer (bittering inhibitor). Therefore, in the Mg replenishing blowing agent composition of the present invention, it is important to add and mix such potassium carbonate and calcium carbonate, whereby the intended effect of the present invention is achieved. Particularly preferred compositions of the composition of the present invention to which these are added are as follows.

【0020】 硫酸マグネシウム(Mgとして) 0.6〜 6重量% 炭酸水素ナトリウム(Naとして) 0〜10重量% 炭酸カリウム(Kとして) 0.1〜 7.3重量% 炭酸カルシウム(Caとして) 0.1〜 5.2重量% 但し、発泡成分としての上記炭酸水素ナトリウム、炭酸
カリウム及び炭酸カルシウムは全体で10重量%以上と
する。
Magnesium sulfate (as Mg) 0.6-6% by weight Sodium hydrogen carbonate (as Na) 0-10% by weight Potassium carbonate (as K) 0.1-7.3% by weight Calcium carbonate (as Ca) 0 However, the total amount of the sodium hydrogen carbonate, potassium carbonate, and calcium carbonate as the foaming component is 10% by weight or more.

【0021】また中和剤成分は15〜60%、好ましく
は20〜50%の範囲から選択されるのがよく、特にL
−酒石酸及び/又はクエン酸を20〜30%、及びL−
アスコルビン酸を5〜25%の範囲内で使用するのが最
も好ましい。上記発泡剤成分及び中和剤成分の配合によ
り本発明所期の優れた効果が達成される。
The neutralizing agent component is selected from the range of 15 to 60%, preferably 20 to 50%,
-20-30% of tartaric acid and / or citric acid, and L-
Most preferably, ascorbic acid is used in the range of 5 to 25%. By combining the foaming agent component and the neutralizing agent component, the excellent effects expected according to the present invention are achieved.

【0022】本発明組成物は、上記各成分を必須成分と
して、之等に更に通常知られている各種の添加剤成分、
例えば糖類、糖アルコール類、甘味料等の他、賦形剤、
結合剤、崩壊剤、滑沢剤、増粘剤、表面活性剤、浸透圧
調節剤、電解質、香料、色素、pH調節剤等を必要に応
じて適宜添加配合できる。上記添加剤としては、例えば
小麦澱粉、馬鈴薯澱粉、コーンスターチ、デキストリン
等の澱粉類、ショ糖、ブドウ糖、果糖、麦芽糖、キシロ
ース、乳糖等の糖類、ソルビトール、マンニトール、マ
ルチトール、キシリトール等の糖アルコール類、カップ
リングシュガー、パラチノース等の糖転位配糖体、リン
酸カルシウム、硫酸カルシウム等の賦形剤、澱粉、糖
類、ゼラチン、アラビアガム、デキストリン、メチルチ
セルロース、ポリビニルピロリドン、ポリビニルアルコ
ール、ヒドロキシプロピルセルロース、キサンタンガ
ム、ペクチン、トラガントガム、カゼイン、アルギン酸
等の結合剤乃至増粘剤、ロイシン、イソロイシン、L−
バリン、シュガーエステル、硬化油、ステアリン酸、ス
テアリン酸マグネシウム、タルク、マクロゴール等の滑
沢剤、アビセル、CMC、CMC−Na、CMC−Ca
等の崩壊剤、ポリソルベート、レシチン等の表面活性
剤、アスパルテーム、アリテーム等のジペプチド、その
他ステビア、サッカリン等の甘味料等を例示でき、之等
は上記必須成分との関係や製剤の性質、製造法等を考慮
してその適当量を適宜選択使用できる。
The composition of the present invention comprises the above-mentioned components as essential components, and various other commonly known additive components,
For example, sugars, sugar alcohols, sweeteners and the like, excipients,
A binder, a disintegrant, a lubricant, a thickener, a surfactant, an osmotic pressure regulator, an electrolyte, a fragrance, a dye, a pH regulator, and the like can be appropriately added and blended as necessary. Examples of the additives include starches such as wheat starch, potato starch, corn starch, dextrin, sugars such as sucrose, glucose, fructose, maltose, xylose, and lactose; sugar alcohols such as sorbitol, mannitol, maltitol, and xylitol. , Coupling sugars, transglycosides such as palatinose, excipients such as calcium phosphate and calcium sulfate, starch, saccharides, gelatin, gum arabic, dextrin, methylthicellulose, polyvinylpyrrolidone, polyvinyl alcohol, hydroxypropylcellulose, xanthan gum , Pectin, gum tragacanth, casein, alginic acid and other binders or thickeners, leucine, isoleucine, L-
Lubricants such as valine, sugar ester, hardened oil, stearic acid, magnesium stearate, talc, macrogol, Avicel, CMC, CMC-Na, CMC-Ca
Disintegrants, such as polysorbate, surfactants such as lecithin, dipeptides such as aspartame and alitame, and other sweeteners such as stevia and saccharin. In consideration of the above, an appropriate amount can be appropriately selected and used.

【0023】更に、本発明製剤にはビタミン類の適当量
を添加配合できる。このビタミン類には、前述した中和
剤としてのLーアスコルビン酸(ビタミンC)も包含さ
れ、これは抗酸化剤として機能する。
Further, an appropriate amount of vitamins can be added to the preparation of the present invention. The vitamins also include L-ascorbic acid (vitamin C) as the above-described neutralizing agent, which functions as an antioxidant.

【0024】特に好ましい本発明Mg補給発泡剤組成物
の代表的組成としては、次のものを挙げることができ
る。
Particularly preferred representative compositions of the Mg-supplemented blowing agent composition of the present invention include the following.

【0025】 硫酸マグネシウム 0.6〜6重量% 発泡剤成分 10〜35重量% クエン酸 20〜30重量% L−アスコルビン酸 5〜25重量% 砂糖等の糖乃至糖アルコール類 8〜40重量% アスパルテーム等の甘味料 0.5〜1重量% 着香料及び着色料 適量 本発明組成物は、通常の製剤製造技術に従って製造する
ことができる。例えば発泡錠剤形態の本発明製剤は、所
定量の各成分を秤量、混合し、直接粉末圧縮法、乾式又
は湿式顆粒圧縮法等に従って製造できる。
Magnesium sulfate 0.6 to 6% by weight Blowing agent component 10 to 35% by weight Citric acid 20 to 30% by weight L-ascorbic acid 5 to 25% by weight Sugar such as sugar or sugar alcohol 8 to 40% by weight Aspartame 0.5-1% by weight of flavoring agent, coloring agent, etc. Suitable amount The composition of the present invention can be produced according to a usual pharmaceutical production technique. For example, the preparation of the present invention in the form of an effervescent tablet can be produced by weighing and mixing a predetermined amount of each component, and directly following a powder compression method, a dry or wet granulation compression method, or the like.

【0026】かくして得られる本発明組成物は、その製
剤形態に応じて一般には経口投与される。特に発泡錠剤
は、これを水中に投入するだけで、経口投与に適した飲
料形態とすることができる。その投与(服用)量は、こ
れを適用すべき生体の年齢、性別、体重や服用目的等に
応じて適宜決定され、特に限定されないが、一般には1
錠約1.5〜6.0gに調製された本発明錠剤の1〜2
錠剤を1回に水100〜300mlに溶かして服用させ
ればよい。
The composition of the present invention thus obtained is generally administered orally depending on its form of preparation. In particular, an effervescent tablet can be made into a beverage form suitable for oral administration simply by putting it into water. The administration (dose) amount is appropriately determined according to the age, sex, body weight, purpose of ingestion and the like of the living body to which this is to be applied, and is not particularly limited.
Tablets 1-2 of the tablet of the present invention prepared to about 1.5 to 6.0 g
The tablet may be dissolved in 100 to 300 ml of water at a time and taken.

【0027】本発明組成物は、特に上述した錠剤に限定
されるものではなく、前記組成範囲を有する限り、例え
ば顆粒剤、散剤、カプセル剤等の形態であってもよく、
之等はいずれも水に溶解、分散させて服用され得る適当
な形態である。
The composition of the present invention is not particularly limited to the above-mentioned tablets, and may be in the form of, for example, granules, powders, capsules, etc. as long as it has the above-mentioned composition range.
These are all suitable forms that can be dissolved and dispersed in water and taken.

【0028】本発明によれば、新しいMg補給発泡剤組
成物が提供され、この発泡剤組成物は安定で、保存性に
優れ、しかも溶けやすく、服用も容易である利点があ
る。また本発明組成物は、その服用により充分なMgを
安全に生体に供給、吸収させ得、Mg欠乏症等の治療乃
至改善効果を奏し得、更に低カロリーである特徴を有し
ている。しかも、本発明発泡剤組成物は総じて味がよ
く、Mgの苦味等をマスクして清涼感のあるおだやかな
味を有する特徴がある。
According to the present invention, there is provided a new Mg-supplemented blowing agent composition, which has the advantage that it is stable, has excellent storage stability, is easily dissolved, and is easy to take. In addition, the composition of the present invention is capable of safely supplying and absorbing sufficient Mg to a living body by taking the composition, has an effect of treating or improving Mg deficiency and the like, and has a feature of being low in calories. Moreover, the foaming agent composition of the present invention generally has a good taste, and has a characteristic of having a refreshing and mild taste by masking the bitterness of Mg and the like.

【0029】[0029]

【実施例】以下、本発明を更に詳しく説明するため実施
例を挙げる。尚、各例中部及び%は特記しない限り重量
部及び重量%を示す。
The present invention will be described in more detail with reference to the following examples. In the examples, “parts” and “%” indicate “parts by weight” and “% by weight” unless otherwise specified.

【0030】[0030]

【実施例1】下記成分を混合し、混合物を直接粉末圧縮
法により製錠して本発明発泡製剤(K+ 3mEq 、Mg2+
8mEq 及びNa+ 12mEq 、一錠当り100mg、Mg
含量2%)を調製した。
Example 1 The following components were mixed, and the mixture was tableted by a direct powder compression method to produce a foamed preparation of the present invention (K + 3 mEq, Mg 2+
8 mEq and Na + 12 mEq, 100 mg per tablet, Mg
(Content 2%).

【0031】 グラニュー糖 28% L−アスコルビン酸 10% 無水クエン酸 23% 硫酸マグネシウム(3水塩) 14% 炭酸マグネシウム 0.4% 炭酸水素ナトリウム 18% 炭酸カリウム(無水) 4% 甘味料 微量 香料 微量 全体 100%(全量4.8g)Granulated sugar 28% L-ascorbic acid 10% Citric anhydride 23% Magnesium sulfate (trihydrate) 14% Magnesium carbonate 0.4% Sodium bicarbonate 18% Potassium carbonate (anhydrous) 4% Sweetener trace amount Flavor trace amount 100% in total (4.8 g in total)

【0032】[0032]

【試験例1】 安定性試験 実施例1で得た本発明製剤組成物の安定性を、炭酸カリ
ウムを添加することなく同様にして調整した錠剤(比較
製剤組成物とする)を対照として、以下の通り比較試験
した。
Test Example 1 Stability Test The stability of the pharmaceutical composition of the present invention obtained in Example 1 was adjusted in the same manner without adding potassium carbonate (hereinafter referred to as a comparative pharmaceutical composition). A comparative test was performed as follows.

【0033】即ち、各錠剤をアルミブリスター包装で別
個に包装し(シリカゲルシート内包)、恒温室に保存
(50℃、2週間又は37℃3ヶ月)し、安定性の効果
を下記評価項目について試験した。
That is, each tablet was separately packaged in an aluminum blister package (silica gel sheet included), stored in a thermostatic chamber (50 ° C., 2 weeks or 37 ° C., 3 months), and tested for the effect of stability on the following evaluation items. did.

【0034】(1)包材の膨れ 包材中のガス発生量として包材の膨れを目視判定した。(1) Swelling of Packaging Material The swelling of packaging material was visually determined as the amount of gas generated in the packaging material.

【0035】(2)錠剤の変色 経変開始前の錠剤(打錠後4℃保存)をスタンダードと
して錠剤表面の色の経時変化を目視判定した。
(2) Discoloration of tablet The change with time of the color of the tablet surface was visually determined using the tablet before storage start (stored at 4 ° C after tableting) as a standard.

【0036】(3)溶解時間 8〜9℃の冷水約140mlに錠剤を投入し、完全に溶
解するまでの時間を測定した。
(3) Dissolution time The tablets were put into about 140 ml of cold water at 8 to 9 ° C., and the time required for complete dissolution was measured.

【0037】(4)味の変化 経時変化開始前の錠剤(打錠後4℃冷所保存品)との比
較を2名で官能試験により行ない下記5段階の点数評価
により表わした。
(4) Change in taste Two tablets were compared by a sensory test with the tablet before the change with the lapse of time (preserved in a cold place at 4 ° C. after tableting), and the results were expressed by the following five-point evaluation.

【0038】 1点;変化なし 2点;僅かに変化あるが問題なし 3点;変化が認められる 4点;明らかに変化が認められる 5点;大いに変化あり 結果を下記表1(包材の膨れ)、表2(錠剤の変色)、
表3(溶解時間)及び表4(味の変化)に示す。
1 point; no change 2 points; slight change but no problem 3 points; change 4 points; clear change 5 points; significant change The results are shown in Table 1 below. ), Table 2 (discoloration of tablets),
The results are shown in Table 3 (dissolution time) and Table 4 (change in taste).

【0039】[0039]

【表1】 [Table 1]

【0040】[0040]

【表2】 [Table 2]

【0041】[0041]

【表3】 [Table 3]

【0042】[0042]

【表4】 [Table 4]

【0043】[0043]

【実施例2】下記成分を混合し、混合物を直接粉末圧縮
法により製錠して本発明発泡製剤(K+ 3mEq 、Mg2+
8mEq 及びNa+ 9mEq 、一錠当り100mg、Mg
含量2%)を調製した。
Example 2 The following components were mixed, and the mixture was tableted by a direct powder compression method to prepare a foamed preparation of the present invention (K + 3 mEq, Mg 2 +
8 mEq and Na + 9 mEq, 100 mg per tablet, Mg
(Content 2%).

【0044】 グラニュー糖 27% L−アスコルビン酸 10% 無水クエン酸 23% 硫酸マグネシウム(3水塩) 14% 炭酸水素ナトリウム 15% 炭酸カリウム(無水) 4% 炭酸カルシウム 2.5% 甘味料 微量 香料 微量 着色料 微量 全体 100%(全量5g)Granulated sugar 27% L-ascorbic acid 10% Citric anhydride 23% Magnesium sulfate (trihydrate) 14% Sodium hydrogen carbonate 15% Potassium carbonate (anhydrous) 4% Calcium carbonate 2.5% Sweetener trace amount Flavor trace amount Coloring agent trace total 100% (total 5g)

【0045】[0045]

【試験例2】 安定性試験 実施例2で得た本発明製剤組成物の安定性を、炭酸カル
シウムを添加することなく同様にして調整した錠剤(比
較製剤組成物とする)を対照として、以下の通り比較試
験した。
Test Example 2 Stability Test The stability of the pharmaceutical composition of the present invention obtained in Example 2 was adjusted in the same manner without adding calcium carbonate (hereinafter referred to as a comparative pharmaceutical composition). A comparative test was performed as follows.

【0046】即ち、各錠剤をアルミブリスター包装で別
個に包装し(シリカゲルシート内包) 、恒温室に保存(50℃、2週間)し、安定性の効果を
前記試験例1に記載の(1)包材の膨れ、(2)錠剤の
変色、(3)溶解時間及び(4)味の変化の各試験項目
について同様にして試験した。
That is, each tablet was individually packaged in an aluminum blister package (silica gel sheet inclusion), stored in a thermostatic chamber (50 ° C., 2 weeks), and the effect of stability was described in the above Test Example 1 (1). Each of the test items of swelling of the packaging material, (2) discoloration of the tablet, (3) dissolution time and (4) change in taste was similarly tested.

【0047】尚、(2)錠剤の変色については、更に色
差計(カラーエースMODEL TC-1、東京電色株式会社製)
を使用して、経変開始前の錠剤(打錠後4℃保存)をス
タンダードとして錠剤の表面の色の経時変化をNBS単
位(ΔE=色差)及びLabで評価した。その目視によ
る感覚の差との関連の目安は、例えば以下の如くであ
る。
(2) Regarding the discoloration of the tablet, a color difference meter (Color Ace MODEL TC-1, manufactured by Tokyo Denshoku Co., Ltd.)
Was used to evaluate the change over time in the color of the tablet surface in NBS units (ΔE = color difference) and Lab, using the tablet before the start of transformation (stored at 4 ° C. after tableting) as a standard. The guideline of the relationship with the difference in visual perception is, for example, as follows.

【0048】 NBS単位 感覚の差 0〜0.5 微かに 0.5〜1.5 僅かに 1.5〜3.0 感知せられるほどに 3.0〜6.0 目立つほどに 6.0〜12.0 大いに 12.0以上 多大に 結果を下記表5(包材の膨れ)、表6(錠剤の変色)、
表7(溶解時間)及び表8(味の変化)に示す。
NBS unit Difference in sensation 0-0.5 Slightly 0.5-1.5 Slightly 1.5-3.0 Sensitive 3.0-6.0 Prominent 6.0- 12.0 Greatly 12.0 or more Significantly, the results are shown in Table 5 (bulging of packaging material), Table 6 (discoloration of tablets),
The results are shown in Table 7 (dissolution time) and Table 8 (change in taste).

【0049】[0049]

【表5】 [Table 5]

【0050】[0050]

【表6】 [Table 6]

【0051】[0051]

【表7】 [Table 7]

【0052】[0052]

【表8】 [Table 8]

【0053】[0053]

【実施例3〜5】実施例1と同様にして、下記表9に示
す各成分より、本発明Mg補給発泡剤組成物を調製し
た。
Examples 3 to 5 In the same manner as in Example 1, an Mg-supplemented blowing agent composition of the present invention was prepared from the components shown in Table 9 below.

【0054】[0054]

【表9】 [Table 9]

【0055】各実施例で得られた本発明製剤は、K及び
Mgの補給食品乃至医薬品として、美味(清涼感等)を
有し、手軽に上記K及びMgを補給できる点より有効で
ある。殊に実施例1〜5で得られた発泡製剤形態の本発
明製剤は、乾燥状態で提供され、水溶液状態と比べて、
内容物の安定性に優れ、味及び栄養効果の点でも優れて
いる。更に之等の製剤はこれを水中に投入すると速やか
に溶解分散し、溶液が総じて透明となる優れた溶解性を
有し、この溶解後の液性より呈色等による不快感もな
く、また色素等の添加によれば、その飲用時の液の色を
任意に調節でき、その外観も好ましい。加えて、本発明
製剤は軽量で安定性に富み、運搬等にも便利で、市場流
通に好ましい。また、本発明製剤は、極めて味がよく、
苦味等がマスクされ、清涼感のあるおだやかな味を有す
るものであった。
The preparations of the present invention obtained in each of the examples are effective as K and Mg supplement foods or pharmaceuticals have a delicious taste (cool feeling, etc.) and can easily supplement the above K and Mg. Particularly, the preparation of the present invention in the form of an effervescent preparation obtained in Examples 1 to 5 is provided in a dry state,
The stability of the contents is excellent, and the taste and nutritional effects are also excellent. Furthermore, these preparations dissolve and disperse promptly when they are put into water, and have excellent solubility in which the solution becomes totally transparent.There is no discomfort due to coloration or the like due to the liquidity after dissolution, and And the like, the color of the liquid at the time of drinking can be arbitrarily adjusted, and its appearance is also preferable. In addition, the preparation of the present invention is lightweight, highly stable, convenient for transportation and the like, and is preferable for market distribution. In addition, the preparation of the present invention has a very good taste,
Bitterness and the like were masked and had a refreshing and mild taste.

───────────────────────────────────────────────────── フロントページの続き (51)Int.Cl.6 識別記号 FI A61K 9/14 A61K 33/06 ADD 9/16 A23L 2/00 F 9/46 2/40 9/50 A61K 9/14 L 33/06 ADD ──────────────────────────────────────────────────の Continued on the front page (51) Int.Cl. 6 Identification code FI A61K 9/14 A61K 33/06 ADD 9/16 A23L 2/00 F 9/46 2/40 9/50 A61K 9/14 L33 / 06 ADD

Claims (4)

【特許請求の範囲】[Claims] 【請求項1】 硫酸マグネシウムをマグネシウムとして
0.6〜6重量%、発泡剤成分10〜35重量%及び中
和剤成分15〜60重量%を含有する発泡製剤であるこ
とを特徴とするマグネシウム補給発泡剤組成物。
1. A magnesium supplement which is a foaming preparation containing 0.6 to 6% by weight of magnesium sulfate as magnesium, 10 to 35% by weight of a foaming agent component and 15 to 60% by weight of a neutralizing agent component. Blowing agent composition.
【請求項2】 中和剤成分がクエン酸及びL−酒石酸2
0〜30重量%及びL−アスコルビン酸5〜25%であ
る請求項1記載の発泡製剤。
2. A neutralizing agent comprising citric acid and L-tartaric acid 2
The effervescent preparation according to claim 1, which is 0 to 30% by weight and 5 to 25% of L-ascorbic acid.
【請求項3】 安定剤として炭酸カリウム0.2〜13
重量%及び炭酸カルシウム0.2〜13重量%を更に含
有する請求項1又は2に記載の発泡製剤。
3. Potassium carbonate 0.2 to 13 as a stabilizer
The effervescent preparation according to claim 1 or 2, further comprising 0.2% to 13% by weight of calcium carbonate.
【請求項4】 錠剤、顆粒剤、散剤又はカプセル剤形態
である請求項1〜3のいずれかに記載の発泡製剤。
4. The effervescent preparation according to claim 1, which is in the form of a tablet, granule, powder or capsule.
JP9159454A 1997-06-17 1997-06-17 Foaming agent composition for supplying magnesium Pending JPH114666A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP9159454A JPH114666A (en) 1997-06-17 1997-06-17 Foaming agent composition for supplying magnesium

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP9159454A JPH114666A (en) 1997-06-17 1997-06-17 Foaming agent composition for supplying magnesium

Publications (1)

Publication Number Publication Date
JPH114666A true JPH114666A (en) 1999-01-12

Family

ID=15694123

Family Applications (1)

Application Number Title Priority Date Filing Date
JP9159454A Pending JPH114666A (en) 1997-06-17 1997-06-17 Foaming agent composition for supplying magnesium

Country Status (1)

Country Link
JP (1) JPH114666A (en)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002532429A (en) * 1998-12-15 2002-10-02 ギリアード サイエンシーズ, インコーポレイテッド Pharmaceutical formulations
JP2008502337A (en) * 2004-06-15 2008-01-31 ネステク ソシエテ アノニム Self-foaming liquid creamer and method
JP2009005675A (en) * 2007-04-13 2009-01-15 Coca Cola Co:The Sweetener composition having improved taste
JP2012532593A (en) * 2009-07-10 2012-12-20 バイオガイア・エイ・ビー Product for storing freeze-dried lactic acid bacteria mixed with powder for oral rehydration solution
JP2014018141A (en) * 2012-07-18 2014-02-03 Kracie Foods Ltd Browning inhibitor and method for inhibiting browning
WO2015020191A1 (en) * 2013-08-09 2015-02-12 日東薬品工業株式会社 Calcium agent

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002532429A (en) * 1998-12-15 2002-10-02 ギリアード サイエンシーズ, インコーポレイテッド Pharmaceutical formulations
JP4750946B2 (en) * 1998-12-15 2011-08-17 ギリアード サイエンシーズ, インコーポレイテッド Pharmaceutical formulation
JP2008502337A (en) * 2004-06-15 2008-01-31 ネステク ソシエテ アノニム Self-foaming liquid creamer and method
JP2009005675A (en) * 2007-04-13 2009-01-15 Coca Cola Co:The Sweetener composition having improved taste
JP2012532593A (en) * 2009-07-10 2012-12-20 バイオガイア・エイ・ビー Product for storing freeze-dried lactic acid bacteria mixed with powder for oral rehydration solution
JP2014018141A (en) * 2012-07-18 2014-02-03 Kracie Foods Ltd Browning inhibitor and method for inhibiting browning
WO2015020191A1 (en) * 2013-08-09 2015-02-12 日東薬品工業株式会社 Calcium agent
JPWO2015020191A1 (en) * 2013-08-09 2017-03-02 日東薬品工業株式会社 Calcium preparation

Similar Documents

Publication Publication Date Title
JP7141542B2 (en) Slightly effervescent buccal tablet and its preparation method
JP3224767B2 (en) Oral zinc composition
ES2395862T3 (en) Mixture of iron and copper salts to mask the metallic taste
WO2018077310A1 (en) Vitamin c sodium-containing effervescent tablet and preparation method therefor
JPH06500552A (en) Calcium and trace mineral supplements
JP2009511515A (en) A mixture of iron and copper salts masking the taste of metals
MXPA05003088A (en) Leucine-enriched nutritional compositions.
JP2983503B2 (en) Iron-calcium mineral supplement with high bioavailability
EP1707192B1 (en) Pharmaceutical composition
KR0143232B1 (en) Preparation for iron supply, preparation for vitamin supply and method for stabilizing a foam preparation
US20080305151A1 (en) Dipeptide-Comprising Composition for Oral Administration
JP5697835B2 (en) Oral preparation for preventing or improving dry skin
US5087442A (en) Preparation for iron supply, preparation for vitamin supply and method for stabilizing a foam preparation
AU755724B2 (en) Combination of zinc ions and vitamin C and method of making
ES2215079T3 (en) GASTRORRESISTENT TABLETS FOR FOOD, DIETETIC AND THERAPEUTIC USE.
US5424074A (en) Pharmaceutical composition for potassium supplementation
JPH114666A (en) Foaming agent composition for supplying magnesium
JPH08503964A (en) Dietary hypocholesterolemic composition
JP2818892B2 (en) Foam formulation
JP2617810B2 (en) Potassium supplement foam
CN112293747A (en) Tablet for supplementing iron and folic acid
CN1449691A (en) Anti-heatstroke effervescent beverage
WO1996003059A1 (en) Compositions for alkalinizing and energy-boosting drinks
RU2796676C1 (en) Water-soluble tablets of colecalciferol and method for their production
JPS61134313A (en) Agent for suppressing toxicity of aldehyde